Skip to main content

99%+ HPLC Pure | Batch-Specific Third-Party COAs | Free Shipping Over $250

Menu

Kynetide Research Team | 16 days ago

Study Ranks 26 Peptide Therapeutics for On-Demand Production During Deep Space Missions

A new npj Microgravity study scores 26 peptide-based medications for feasibility of recombinant in-situ production during multi-year space missions.

Future crewed missions beyond Earth orbit — to the Moon, Mars, and beyond — will last years rather than weeks, and that timeline breaks the traditional pharmaceutical supply chain. Medications degrade faster in space due to radiation exposure and imperfect storage conditions, and hauling large stockpiles of temperature-controlled biologics across millions of miles is simply not practical. That has researchers looking seriously at in-situ, or "on-demand," drug manufacturing as a way to keep deep space crews medically self-sufficient.


A new study published July 9, 2026 in npj Microgravity, led by researchers from the University of Nottingham's School of Pharmacy along with collaborators at UCLA's David Geffen School of Medicine and Stanford University School of Medicine, takes a structured look at which peptide therapeutics are best suited for this kind of production in orbit or transit. The team evaluated 26 spaceflight-relevant peptide-based medications against a purpose-built scoring framework.

How the Ranking Framework Works

The researchers scored each peptide against ten criteria split across two categories. The first, Operational and Clinical Relevance (OCR), covers regulatory status, shelf stability, storage requirements, a NASA Human Research Roadmap risk/impact score, and purification requirements — essentially, how badly a mission would need the drug and how hard it currently is to keep it usable in space. The second category, Recombinant Production Feasibility (RPF), covers amino acid chain length, prior history of recombinant production, availability of functional assays, dosing requirements, and complexity of post-translational modifications.


Each of the ten criteria was scored from 0 to 2 points, giving every therapeutic a combined score out of 20. Peptides with short chains, well-established production methods, and low post-translational modification complexity naturally scored better on the manufacturability side, while those with strong mission-relevance and storage challenges scored higher on the clinical side.

Teriparatide Tops the List, Metabolic Peptides Follow

Teriparatide, a parathyroid hormone fragment, came out on top with a score of 17 out of 20, followed closely by abaloparatide and amylin, each scoring 16. A second tier of candidates — including angiotensin II, daptomycin, GLP-1 agonists, G-CSF, GM-CSF, and salmon calcitonin — scored 14 out of 20, reflecting solid but slightly less ideal combinations of relevance and producibility.


The authors frame this as a structured starting point rather than a final verdict, offering future astropharmacy research a way to prioritize which peptides deserve investment in recombinant production methods suited for orbital or deep-space environments. For a research-focused peptide industry, it's a useful signal of where synthesis, formulation, and stability work may be headed next. For research use only. Not for human consumption.

FAQ

Q: What does "on-demand" peptide production in space mean?

A: It refers to manufacturing a therapeutic peptide in-situ, aboard a spacecraft or habitat, using recombinant biological production methods, rather than shipping a pre-made, pre-packaged supply from Earth.


Q: Why do medications degrade faster in space than on Earth?

A: The study cites radiation exposure and difficult-to-maintain storage conditions (such as temperature control) as key factors that accelerate degradation of many pharmaceuticals during long-duration spaceflight.


Q: What is the difference between the OCR and RPF scores?

A: OCR (Operational and Clinical Relevance) measures how mission-critical and currently hard-to-store a peptide is, while RPF (Recombinant Production Feasibility) measures how straightforward that peptide would be to manufacture recombinantly, based on factors like chain length and prior production history.


Q: Why did teriparatide score highest?

A: It combined a relatively short amino acid chain, an established history of recombinant production, and a favorable profile across the study's clinical and operational criteria, landing a combined score of 17 out of 20.

Sources

Donovan, J.J., Ericson, I., Wenthe, A. et al. "On-demand peptide therapeutics for multi-year space exploration: analysis of clinical and operational relevance and recombinant production feasibility." npj Microgravity (2026). nature.com

Let’s create what matters — together.

Kynetide Research Team

More Posts

How to Read a Peptide COA: A Researcher's Guide to Certificates of AnalysisHow to Read a Peptide COA: A Researcher's Guide to Certificates of Analysis
How to Read a Peptide COA: A Researcher's Guide to Certificates of Analysis

A Certificate of Analysis (COA) is the single most important document that comes with a research peptide order, yet it's also one of the most overlooked. Knowing how to read one — and what to look for — turns an unfamiliar lab report into a clear signal of quality and identity. Here's a practical breakdown of what every COA should tell you.

Jul 31 | Kynetide Research Team
Peptide Reconstitution 101: Bacteriostatic Water, Dilution Math & StoragePeptide Reconstitution 101: Bacteriostatic Water, Dilution Math & Storage
Peptide Reconstitution 101: Bacteriostatic Water, Dilution Math & Storage

Reconstituting a lyophilized peptide correctly is one of the most important steps in any research protocol. Use too much or too little bacteriostatic water, and your concentration math (and your results) can be thrown off before you even start. Here's a clear walkthrough of the process our research team follows.

Jul 30 | Kynetide Research Team
How to Travel With Research Peptides: Cold-Chain Storage & Transport Guide (2026)How to Travel With Research Peptides: Cold-Chain Storage & Transport Guide (2026)
How to Travel With Research Peptides: Cold-Chain Storage & Transport Guide (2026)

Relocating for a conference, shipping samples between labs, or just moving vials from the freezer to the bench: every step outside cold storage puts peptide integrity at risk. Here's what our research team looks at when planning safe transport for temperature-sensitive compounds.

Jul 30 | Kynetide Research Team
What's Really in Your Compounded GLP-1?What's Really in Your Compounded GLP-1?
What's Really in Your Compounded GLP-1?

This week's reporting on compounded GLP-1 products raises a question that goes beyond weight-loss injections: how do you know a compounded peptide is chemically what it claims to be? Stanford Medicine clinicians and independent lab analyses are documenting real gaps — unapproved salt forms, undisclosed additives, and even newly formed molecules that don't exist in the approved drug. Here's what the research actually found, and why verified sourcing is the real answer.

Jul 29 | Kynetide Research Team
Patient Safety Groups Are Sounding the Alarm on the FDA's Peptide VotePatient Safety Groups Are Sounding the Alarm on the FDA's Peptide Vote
Patient Safety Groups Are Sounding the Alarm on the FDA's Peptide Vote

While everyone's been focused on which peptides made this week's FDA advisory vote, a quieter story has been unfolding alongside it: the agency's own scientists recommended against every peptide under review, and now patient safety groups are formally warning that the panel's decision came without the evidence needed to justify it. Here's what ECRI, ISMP, and the Partnership for Safe Medicines actually said, and what it means for anyone buying peptides today.

Jul 29 | Kynetide Research Team
The Peptide Safety Gap Nobody's Watching Is at Your Local Med SpaThe Peptide Safety Gap Nobody's Watching Is at Your Local Med Spa
The Peptide Safety Gap Nobody's Watching Is at Your Local Med Spa

While everyone's been watching the FDA's advisory committee vote, a new Washington Post investigation points to a bigger, quieter risk: the medspas and wellness clinics actually injecting peptides into consumers face less regulatory oversight than your neighborhood restaurant. Here's what the investigation found, why the gap exists, and what it means for anyone buying peptides today.

Jul 28 | Kynetide Research Team
The Peptide Headlines Don't Match the PaperworkThe Peptide Headlines Don't Match the Paperwork
The Peptide Headlines Don't Match the Paperwork

For months, social media has insisted that Robert F. Kennedy Jr. already "legalized" a wave of popular research peptides. This week's FDA advisory committee vote added fuel to that story, but the actual paper trail tells a more complicated tale. Here's what's really changed, what's still just talk, and what it means if you're buying peptides today.

Jul 28 | Kynetide Research Team
Six Peptides In, One Rejected: What the FDA Vote Really ChangesSix Peptides In, One Rejected: What the FDA Vote Really Changes
Six Peptides In, One Rejected: What the FDA Vote Really Changes

This week's FDA Pharmacy Compounding Advisory Committee meeting ended with six peptides recommended for the agency's 503A Bulk Drug Substances List and one turned away. The vote made headlines, but the fine print matters more than the tally. Here is what the committee actually decided, what it does not decide, and why sourcing still matters no matter how the FDA rules.

Jul 27 | Kynetide Research Team
FDA Peptide Vote Sends Hims & Hers Shares Higher as Wall Street Eyes a Multi-Billion Dollar MarketFDA Peptide Vote Sends Hims & Hers Shares Higher as Wall Street Eyes a Multi-Billion Dollar Market
FDA Peptide Vote Sends Hims & Hers Shares Higher as Wall Street Eyes a Multi-Billion Dollar Market

An FDA advisory panel's split vote on peptide compounding sent Hims & Hers Health shares swinging Thursday, as Wall Street analysts weighed a potential multi-billion dollar telehealth opportunity against lingering safety concerns raised by the agency's own scientists.

Jul 26 | Kynetide Research Team